All In Biotech

NDA 214902 · Mayne Pharma

Twyneo

Benzoyl Peroxide, Tretinoin · Topical · Retinoid

Last checked: Nov 19, 2026Latest source record: Jul 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jul 26, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

162

44 Phase 3, 7 recruiting

FAERS reports

38

2 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 11, 2025.

TWYNEO is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. TWYNEO is a combination tretinoin, a retinoid, and benzoyl peroxide indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. ( 1 )

Mechanism: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects, but the precise mechanism of action is unknown. Tretinoin is a metabolite of vitamin A that binds with high affinity to specific retinoic acid receptors located in both the cytosol and nucleus. Tretinoin activates three members of the retinoic acid (RAR) nuclear receptors (RARα , RARβ, RARγ) which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation. It has not been established whether the clinical effects of tretinoin are mediated through activation of...

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TWYNEO · BENZOYL PEROXIDE 3%; TRETINOIN 0.1% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Benzoyl Peroxide" as an intervention, any sponsor and status, largest first.

All 162 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • skin burning sensation7
  • acne6
  • erythema6
  • dry skin5
  • inappropriate schedule of product administration5
  • intentional product misuse4
  • pain of skin4
  • poor quality product administered4
  • pruritus4
  • drug ineffective3
  • product colour issue3
  • underdose3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202210
202313
202410
20255

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Twyneo (Tretinoin/Benzoyl Peroxide)

2024 spending

$41K

Beneficiaries

37

88 claims

Per beneficiary

$1,115

$14.95 per unit

View as table
YearSpending
2020$0
2021$0
2022$26,607
2023$51,975
2024$41,266

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 363 on PubMed

Sponsor: Mayne Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.